Connect Biopharma | 8-K: FY2025 Q3 Revenue: USD 16 K

LB filings
2025.11.12 14:08
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 16 K.

EPS: As of FY2025 Q3, the actual value is USD -0.31, missing the estimate of USD -0.2375.

License and Collaboration Revenue

  • License and collaboration revenues for the three months ended September 30, 2025, were $16,000, compared to $1.2 million for the same period in 2024. For the nine months ended September 30, 2025, revenues were $64,000, compared to $25.3 million in 2024.

Research and Development Expense

  • Research and development expenses for the three months ended September 30, 2025, were $11.1 million, compared to $9.0 million for the same period in 2024. For the nine months ended September 30, 2025, expenses were $26.5 million, compared to $23.0 million in 2024.

General and Administrative Expense

  • General and administrative expenses for the three months ended September 30, 2025, were $6.6 million, compared to $6.1 million for the same period in 2024. For the nine months ended September 30, 2025, expenses were $16.1 million, compared to $15.1 million in 2024.

Net Loss

  • Net loss for the three months ended September 30, 2025, was $17.2 million, or $0.31 per share, compared to $12.9 million, or $0.23 per share, for the same period in 2024. For the nine months ended September 30, 2025, net loss was $40.4 million, or $0.73 per share, compared to $6.7 million, or $0.12 per share, in 2024.

Cash Flow

  • Cash, cash equivalents, and short-term investments were $54.8 million as of September 30, 2025. The company expects these funds to be sufficient to support operations into 2027.

Outlook / Guidance

  • Connect Biopharma expects to report topline data from Phase 2 Seabreeze STAT studies for asthma and COPD in the first half of 2026. The company anticipates that its cash, cash equivalents, and short-term investments will be sufficient to fund operations into 2027. Connect Biopharma is eligible to receive milestone payments up to approximately $110 million and royalties from Simcere in Greater China.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.